PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS

获得使用储存的人类生物材料的知情同意书的计划

• 批准号: 7606389
• 负责人: MICHAEL P DUBE
• 金额: $ 0.57万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606389
• 关键词: AIDS clinical trial group; Acquired Immunodeficiency Syndrome; Address; Archives; Biological; Blood; Blood specimen; Body Fluids; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; DNA; Enrollment; Funding; Future; Grant; Human; Informed Consent; Institution; Left; Protocols documentation; Research; Research Personnel; Resources; Sampling; Source; Specimen; Tissues; United States National Institutes of Health; Urine; cohort; design; genetic analysis

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This multi-center protocol was designed to obtain the appropriate informed consent to archive left-over human biological materials, blood, urine, tissue, or other body fluids, that are collected during all AACTG trials. An additional blood sample may be collected as a source of human DNA for possible genetic analyses. These samples are an important resource for addressing research questions in the future that cannot be anticipated presently. In addition, the specimens represent unique cohorts, which may not be reproducible in the future. No more than 50,000 subjects will be enrolled all across the AIDS Clinical Trials Units.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该多中心方案旨在获得适当的知情同意，以归档剩余的人类生物学材料，血液，尿液，组织或其他体液，这些同意是在所有AACTG试验期间收集的。 可以将额外的血液样本作为人类DNA的来源收集，以进行遗传分析。 这些样本是解决未来研究问题的重要资源，目前无法预料。 此外，样品代表了独特的同类人群，将来可能无法再现。 在艾滋病临床试验单元中，将不超过50,000名受试者。